Although most private companies in this industry are development-stage concerns, two have related sales of at least $50 million. An additional three commpanies have total sales of over $50 million, including products other than biotechnology pharmaceuticals. This report profiles over 110 private and start-up US companies (e.g., Boehringer Ingelheim, PRAECIS Pharmaceuticals) and lists them by indication and location. The report also forecasts industry demand, evaluates market share, and reviews acquistion and IPO trends.